Cargando…

A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF

BACKGROUND: The extend of lung disease remains the most important prognostic factor for survival in patients with cystic fibrosis (CF), and lack of adherence is the main reason for treatment failure. Early detection of deterioration in lung function and optimising adherence are therefore crucial in...

Descripción completa

Detalles Bibliográficos
Autores principales: Thee, Stephanie, Stahl, Mirjam, Fischer, Rainald, Sutharsan, Sivagurunathan, Ballmann, Manfred, Müller, Axel, Lorenz, Daniel, Urbanski-Rini, Dominika, Püschner, Franziska, Amelung, Volker Eric, Fuchs, Carola, Mall, Marcus Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058751/
https://www.ncbi.nlm.nih.gov/pubmed/33882893
http://dx.doi.org/10.1186/s12890-021-01500-y
_version_ 1783681073486495744
author Thee, Stephanie
Stahl, Mirjam
Fischer, Rainald
Sutharsan, Sivagurunathan
Ballmann, Manfred
Müller, Axel
Lorenz, Daniel
Urbanski-Rini, Dominika
Püschner, Franziska
Amelung, Volker Eric
Fuchs, Carola
Mall, Marcus Alexander
author_facet Thee, Stephanie
Stahl, Mirjam
Fischer, Rainald
Sutharsan, Sivagurunathan
Ballmann, Manfred
Müller, Axel
Lorenz, Daniel
Urbanski-Rini, Dominika
Püschner, Franziska
Amelung, Volker Eric
Fuchs, Carola
Mall, Marcus Alexander
author_sort Thee, Stephanie
collection PubMed
description BACKGROUND: The extend of lung disease remains the most important prognostic factor for survival in patients with cystic fibrosis (CF), and lack of adherence is the main reason for treatment failure. Early detection of deterioration in lung function and optimising adherence are therefore crucial in CF care. We implement a randomized controlled trial to evaluate efficacy of telemonitoring of adherence, lung function, and health condition in combination with behavior change interventions using innovative digital technologies. METHODS: This is a multi-centre, randomized, controlled, non-blinded trial aiming to include 402 patients ≥ 12 years-of-age with CF. A standard-of-care arm is compared to an arm receiving objective, continuous monitoring of adherence to inhalation therapies, weekly home spirometry using electronic devices with data transmission to patients and caring physicians combined with video-conferencing, a self-management app and professional telephone coaching. The duration of the intervention phase is 18 months. The primary endpoint is time to the first protocol-defined pulmonary exacerbation. Secondary outcome measures include number of and time between pulmonary exacerbations, adherence to inhalation therapy, changes in forced expiratory volume in 1 s from baseline, number of hospital admissions, and changes in health-related quality of life. CF-associated medical treatment and care, and health care related costs will be assessed by explorative analysis in both arms. DISCUSSION: This study offers the opportunity to evaluate the effect of adherence interventions using telemedicine capable devices on adherence and lung health, possibly paving the way for implementation of telemedicine in routine care for patients with CF. Trial registration: This study has been registered with the German Clinical Trials Register (Identifier: DRKS00024642, date of registration 01 Mar 2021, URL: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00024642). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01500-y.
format Online
Article
Text
id pubmed-8058751
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80587512021-04-21 A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF Thee, Stephanie Stahl, Mirjam Fischer, Rainald Sutharsan, Sivagurunathan Ballmann, Manfred Müller, Axel Lorenz, Daniel Urbanski-Rini, Dominika Püschner, Franziska Amelung, Volker Eric Fuchs, Carola Mall, Marcus Alexander BMC Pulm Med Study Protocol BACKGROUND: The extend of lung disease remains the most important prognostic factor for survival in patients with cystic fibrosis (CF), and lack of adherence is the main reason for treatment failure. Early detection of deterioration in lung function and optimising adherence are therefore crucial in CF care. We implement a randomized controlled trial to evaluate efficacy of telemonitoring of adherence, lung function, and health condition in combination with behavior change interventions using innovative digital technologies. METHODS: This is a multi-centre, randomized, controlled, non-blinded trial aiming to include 402 patients ≥ 12 years-of-age with CF. A standard-of-care arm is compared to an arm receiving objective, continuous monitoring of adherence to inhalation therapies, weekly home spirometry using electronic devices with data transmission to patients and caring physicians combined with video-conferencing, a self-management app and professional telephone coaching. The duration of the intervention phase is 18 months. The primary endpoint is time to the first protocol-defined pulmonary exacerbation. Secondary outcome measures include number of and time between pulmonary exacerbations, adherence to inhalation therapy, changes in forced expiratory volume in 1 s from baseline, number of hospital admissions, and changes in health-related quality of life. CF-associated medical treatment and care, and health care related costs will be assessed by explorative analysis in both arms. DISCUSSION: This study offers the opportunity to evaluate the effect of adherence interventions using telemedicine capable devices on adherence and lung health, possibly paving the way for implementation of telemedicine in routine care for patients with CF. Trial registration: This study has been registered with the German Clinical Trials Register (Identifier: DRKS00024642, date of registration 01 Mar 2021, URL: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00024642). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01500-y. BioMed Central 2021-04-21 /pmc/articles/PMC8058751/ /pubmed/33882893 http://dx.doi.org/10.1186/s12890-021-01500-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Thee, Stephanie
Stahl, Mirjam
Fischer, Rainald
Sutharsan, Sivagurunathan
Ballmann, Manfred
Müller, Axel
Lorenz, Daniel
Urbanski-Rini, Dominika
Püschner, Franziska
Amelung, Volker Eric
Fuchs, Carola
Mall, Marcus Alexander
A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF
title A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF
title_full A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF
title_fullStr A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF
title_full_unstemmed A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF
title_short A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF
title_sort multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: connect cf
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058751/
https://www.ncbi.nlm.nih.gov/pubmed/33882893
http://dx.doi.org/10.1186/s12890-021-01500-y
work_keys_str_mv AT theestephanie amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT stahlmirjam amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT fischerrainald amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT sutharsansivagurunathan amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT ballmannmanfred amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT mulleraxel amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT lorenzdaniel amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT urbanskirinidominika amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT puschnerfranziska amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT amelungvolkereric amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT fuchscarola amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT mallmarcusalexander amulticentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT theestephanie multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT stahlmirjam multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT fischerrainald multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT sutharsansivagurunathan multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT ballmannmanfred multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT mulleraxel multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT lorenzdaniel multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT urbanskirinidominika multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT puschnerfranziska multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT amelungvolkereric multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT fuchscarola multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf
AT mallmarcusalexander multicentrerandomizedcontrolledtrialoncoachingandtelemonitoringinpatientswithcysticfibrosisconnectcf